A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia

Bibliography

• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793–803
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009;103(Suppl 3):12–23
   PubMed Web of Science ®Google Scholar
• Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118–40
   PubMed Web of Science ®Google Scholar
• Silva J, Silva CM, Cruz F. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Curr Opin Urol 2014;24:21–8
   PubMed Web of Science ®Google Scholar
• Descazeaud A, de La Taille A, Giuliano F, et al. [Negative effects on sexual function of medications for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia]. Prog Urol 2015;25:115–27
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006;176:1529–33
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Masumori N, Hisasue S, et al. Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J Sex Med 2008;5:2185–90
   PubMed Web of Science ®Google Scholar
• Hisasue S, Furuya R, Itoh N, et al. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 2006;13:1311–16
   PubMed Web of Science ®Google Scholar
• Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467–74
   PubMed Web of Science ®Google Scholar
• Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of alpha1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf 2014;13:1187–97
   PubMed Web of Science ®Google Scholar
• Cantrell MA, Bream-Rouwenhorst HR, Steffensmeier A, et al. Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother 2008;42:558–63
   PubMed Web of Science ®Google Scholar
• Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892–900
   PubMed Web of Science ®Google Scholar
• Lepor H, Kazzazi A, Djavan B. Alpha-Blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol 2012;22:7–15
   PubMed Web of Science ®Google Scholar
• Narayan P, Tewari A. The United States 93-01 Study Group: a second phase III multicenter placebo controlled study of 2 doses of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998;160:1701–6
   PubMed Web of Science ®Google Scholar
• Tubaro A, De Nunzio C, Puccini F, et al. The evolving picture of lower urinary tract symptom management. Eur Urol 2014;67(2):271–2
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension. Eur Urol 2014;67(2):262–70
   PubMed Web of Science ®Google Scholar
• Hodges LA, Sime KA, Creech LA, et al. Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered tablet. Int J Pharm 2013;454:41–6
   PubMedGoogle Scholar
• Roehrborn CG, van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92:257–61
   PubMed Web of Science ®Google Scholar
• Osman NI, Chapple CR, Cruz F, et al. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother 2012;13:2085–96
   PubMed Web of Science ®Google Scholar
• Pandey DK, Bhatt S, Jindal A, et al. Effect of combination of ketanserin and escitalopram on behavioral anomalies after olfactory bulbectomy: Prediction of quick onset of antidepressant action. Indian J Pharmacol 2014;46:639–43
   PubMed Web of Science ®Google Scholar
• Schauer I, Madersbacher S. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015. Curr Opin Urol 2015;25:6–11
   PubMed Web of Science ®Google Scholar
• Novara G, Chapple CR, Montorsi F. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). BJU Int 2014;114:427–33
   PubMed Web of Science ®Google Scholar
• Novara G, Chapple CR, Montorsi F. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms associated with benign prostatic enlargement: subgroup analyses of efficacy and safety data. BJU Int 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Capitanio U, Salonia A, Briganti A, et al. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract 2013;67:544–51
   PubMed Web of Science ®Google Scholar
• Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 2014;11:1554–66
   PubMed Web of Science ®Google Scholar
• Kumar S, Tiwari DP, Ganesamoni R, et al. Prospective randomized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology 2013;82:171–5
   PubMed Web of Science ®Google Scholar
• Huang JJ, Huang YJ, Zhu L, et al. Design, synthesis and alpha1-adrenoreceptor blocking activity of new arylpiperazines containing acetophenone substituents. Pharmazie 2014;69:578–84
   PubMed Web of Science ®Google Scholar
• Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007;92:1659–65
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185–91
   PubMed Web of Science ®Google Scholar
• Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992;147:1298–302
   PubMed Web of Science ®Google Scholar
• Marks LS, Partin AW, Dorey FJ, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999;53:574–80
   PubMed Web of Science ®Google Scholar
• Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010;28:9–15
   PubMed Web of Science ®Google Scholar
• Oelke M, Gravas S. Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society. World J Urol 2010;28:1–2
   PubMed Web of Science ®Google Scholar
• Oztekin CV, Gur S, Abdulkadir NA, et al. Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy. J Sex Med 2012;9:1773–81
   PubMed Web of Science ®Google Scholar
• Pinsky MR, Gur S, Tracey AJ, et al. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med 2011;8:3066–74
   PubMed Web of Science ®Google Scholar
• Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004;172:915–19
   PubMed Web of Science ®Google Scholar
• Tacklind J, Fink HA, Macdonald R, et al. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev 2010(10):CD006015
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434–41
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. The clinical benefits of dutasteride treatment for LUTS and BPH. Rev Urol 2004;6(Suppl 9):S22–30
   PubMedGoogle Scholar
• Toren P, Margel D, Kulkarni G, et al. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ 2013;346:f2109
   PubMedGoogle Scholar
• Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011;108:388–94
   PubMed Web of Science ®Google Scholar
• Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Meehan AG, et al. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 2009;73:935–9
   PubMed Web of Science ®Google Scholar
• Thompson IMJr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013;369:603–10
   PubMed Web of Science ®Google Scholar
• Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192–202
   PubMed Web of Science ®Google Scholar
• Andriole GL, Bostwick DG, Gomella LG, et al. Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study. Urology 2014;84:393–9
   PubMed Web of Science ®Google Scholar
• Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008;1:174–81
   PubMed Web of Science ®Google Scholar
• Klotz L, Saad F. PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. Can Urol Assoc J 2007;1:17–21
   PubMedGoogle Scholar
• Theoret MR, Ning YM, Zhang JJ, et al. The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med 2011;365:97–9
   PubMed Web of Science ®Google Scholar
• Amaral C, Varela C, Correia-da-Silva G, et al. New steroidal 17beta-carboxy derivatives present anti-5alpha-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line. Biochimie 2013;95:2097–106
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98
   PubMed Web of Science ®Google Scholar
• Hollingsworth JM, Wei JT. Does the combination of an alpha1-adrenergic antagonist with a 5alpha-reductase inhibitor improve urinary symptoms more than either monotherapy? Curr Opin Urol 2010;20:1–6
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123–31
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Oyarzabal Perez I, Roos EP, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int 2015. [ Epub ahead of print]
   PubMedGoogle Scholar
• McVary KT, Monnig W, Camps JL, et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177:1071–7
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Chapple C, Oelke M, et al. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Urol 2014;191:1045–50
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228–34
   PubMed Web of Science ®Google Scholar
• Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236–44
   PubMed Web of Science ®Google Scholar
• Zhang LT, Park JK. Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia? World J Nephrol 2015;4:138–47
   Google Scholar
• Vignozzi L, Gacci M, Cellai I, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 2013;73:1391–402
   PubMed Web of Science ®Google Scholar
• Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746–60
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Nomiya M, Andersson KE. Functional consequences of chronic bladder ischemia. Neurourol Urodyn 2014;33:54–8
   PubMed Web of Science ®Google Scholar
• Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994–1003
   PubMed Web of Science ®Google Scholar
• Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917–25
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Kaminetsky JC, Auerbach SM, et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502–7
   PubMed Web of Science ®Google Scholar
• Lee DS, Choe HS, Kim SW, et al. Impact of the change in urinary and sexual function on health-related quality of life after once daily low-dose mirodenafil treatment in patients with organic erectile dysfunction. Urol Int 2014;93:84–91
   PubMed Web of Science ®Google Scholar
• Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006;97(Suppl 2):39–43; discussion 44-35
   PubMedGoogle Scholar
• Casabe A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014;191:727–33
   PubMed Web of Science ®Google Scholar
• Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186–94
   PubMed Web of Science ®Google Scholar
• Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259–64; discussion 264-255
   PubMed Web of Science ®Google Scholar
• Crawford ED, Hirst K, Kusek JW, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol 2011;186:965–70
   PubMed Web of Science ®Google Scholar
• Marberger M, Chartier-Kastler E, Egerdie B, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol 2013;63:496–503
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Chartier-Kastler E, et al. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2014;192:150–6
   PubMed Web of Science ®Google Scholar
• Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009(2):CD001423
   PubMed Web of Science ®Google Scholar
• Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA 2011;306:1344–51
   PubMed Web of Science ®Google Scholar
• MacDonald R, Tacklind JW, Rutks I, et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012;109:1756–61
   PubMed Web of Science ®Google Scholar
• Tacklind J, Macdonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012;12:CD001423
   PubMedGoogle Scholar
• Coulson S, Rao A, Beck SL, et al. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complement Ther Med 2013;21:172–9
   PubMed Web of Science ®Google Scholar
• Bosch RJ, Griffiths DJ, Blom JH, et al. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol 1989;141:68–72
   PubMed Web of Science ®Google Scholar
• Axcrona K, Aaltomaa S, da Silva CM, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int 2012;110:1721–8
   PubMed Web of Science ®Google Scholar
• Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170–7
   PubMed Web of Science ®Google Scholar
• Denmeade SR, Egerdie B, Steinhoff G, et al. Phase I and II studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747–54
   PubMed Web of Science ®Google Scholar
• Elhilali MM, Pommerville P, Yocum RC, et al. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol 2013;189:1421–6
   PubMed Web of Science ®Google Scholar
• United States Securities and Exchange Commission. Washington, DC:Form 8K, USSEC. 2014. Available from: http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001437749-14-022077%2Etxt&FilePath=%5C2014%5C12%5C15%5C&CoName=SOPHIRIS+BIO+INC%2E&FormType=8-K&RcvdDate=12%2F15%2F2014&pdf= [Last accessed 29 April 2015]
   Google Scholar
• Masumori N. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther Clin Risk Manag 2011;7:227–38
   PubMed Web of Science ®Google Scholar
• Tsuritani S, Nozaki T, Okumura A, et al. A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. Urol Int 2010;85:80–7
   PubMed Web of Science ®Google Scholar
• Garimella PS, Fink HA, Macdonald R, et al. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev 2009(4):CD007360
   Google Scholar
• Castiglione F, Benigni F, Briganti A, et al. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Curr Med Res Opin 2014;30:719–32
   PubMed Web of Science ®Google Scholar
• Calmasini FB, Candido TZ, Alexandre EC, et al. The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: New therapeutic indication? Prostate 2015;75:440–7
   PubMed Web of Science ®Google Scholar
• Li Z, Habuchi T, Tsuchiya N, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis 2004;25:237–40
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Wang Z, O’Malley KJ, et al. Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. Prostate 2015;75:381–9
   PubMed Web of Science ®Google Scholar
• Shore N, Cowan B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis 2011;2:377–83
   PubMedGoogle Scholar
• Kunit T, Lusuardi L. An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia. Res Rep Urol 2014;6:67–70
   Google Scholar
• Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH. Hasbrouck Heights, NJ:Nymox Pharmaceutical Corporation Immediate News Release. 2014. Available from: http://www.nymox.com/resources/content/d223.pdf [Last accessed 29 April 2015]
   Google Scholar
• Gravas S, de la Rosette JJ. Investigational therapies targeted to the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2013;22:357–68
   PubMed Web of Science ®Google Scholar
• Fibbi B, Penna G, Morelli A, et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010;33:475–88
   PubMed Web of Science ®Google Scholar
• Ammar AE, Esmat A, Hassona MD, et al. The effect of pomegranate fruit extract on testosterone-induced BPH in rats. Prostate 2015;75(7):679–92
   PubMed Web of Science ®Google Scholar